To confirm that this approach can also be effective in different types of cancer and to investigate whether TT may generate an immunological anti-cancer memory, in the present study we describe a model of a very aggressive neoplasia resistant to anti-PD-1, i.e., a disseminated, orthotopic, Myc-driven B-cell lymphoma, and compared TT with other therapies currently used in the clinic for this disease. The gene discussed is MYC; the disease is B-cell non-Hodgkin lymphoma.